Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide

European Radiology

Volumn 21, Issue 12, 2011, Pages 2455-2465

  Kim, Hyun J ^a   Brown, Matthew S ^a   Elashoff, Robert ^a   Li, Gang ^b   Gjertson, David W ^a   Lynch, David A ^c   Strollo, Diane C ^d   Kleerup, Eric ^a   Chong, Daniel ^a   Shah, Sumit K ^a   Ahmad, Shama ^a   Abtin, Fereidoun ^a   Tashkin, Donald P ^a   Goldin, Jonathan G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Fibrosis; HRCT; Interstitial lung disease; Prentice operational criteria; Texture feature

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO;

ARTICLE; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DRUG EFFICACY; FORCED VITAL CAPACITY; HEALTH ASSESSMENT QUESTIONNAIRE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE QUALITY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SCLERODERMA; SKINFOLD THICKNESS; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; FIBROSIS; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 83555164738     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2223-2     Document Type: Article

References (36)

1. VD Steen C Conte GR Owens TA Medsger Jr 1994 Severe restrictive lung disease in systemic sclerosis Arthritis Rheum 37 1283 1289 7945490 10.1002/art.1780370903 1:STN:280:DyaK2M%2Fjt1aguw%3D%3D (Pubitemid 24320744)
2. VD Steen TA Medsger Jr 2000 Severe organ involvement in systemic sclerosis with diffuse scleroderma Arthritis Rheum 43 2437 2444 11083266 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U 1:STN:280:DC%2BD3M%2FktFequw%3D%3D
3. Medsger TA Jr (2004) Classification, prognosis. In: Clements PJ, Furst DE (eds) Systemic Sclerosis. Lippincott, Williams and Wilkins, Philadelphia, pp 17-28
4. D Bouros AU Wells AG Nicholson TV Colby V Polychronopoulos P Pantelidis PL Haslam DA Vassilakis CM Black RM du Bois 2002 Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome Am J Respir Crit Care Med 165 1581 1586 12070056 10.1164/rccm.2106012 (Pubitemid 34693935)
5. DS Kim B Yoo JS Lee EK Kim CM Lim SD Lee Y Koh WS Kim WD Kim TV Colby M Kitiaichi 2002 The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia Sarcoidosis Vasc Diffuse Lung Dis 19 121 127 12108451 (Pubitemid 34685911)
6. OA Minai RA Dweik AC Arroliga 1998 Manifestations of scleroderma pulmonary disease Clin Chest Med 19 713 731 9917962 10.1016/S0272-5231(05)70112- X 1:STN:280:DyaK1M7hs1CrtQ%3D%3D viii-ix (Pubitemid 29013314)
7. A Fischer JJ Swigris SD Groshong CD Cool H Sahin DA Lynch D Curran-Everett JZ Gillis RT Meehan KK Brown 2008 Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival Chest 134 601 605 18403656 10.1378/chest.08-0053
8. TS Kim KS Lee MP Chung J Han JS Park JH Hwang OJ Kwon CH Rhee 1998 Nonspecific interstitial pneumonia with fibrosis: high-resolution CT and pathologic findings AJR Am J Roentgenol 171 1645 1650 9843306 1:STN:280:DyaK1M%2FlslCnsg%3D%3D (Pubitemid 28531641)
9. T Johkoh NL Muller TV Colby K Ichikado H Taniguchi Y Kondoh K Fujimoto M Kinoshita H Arakawa H Yamada M Suga M Ando M Koyama H Nakamura 2002 Nonspecific interstitial pneumonia: correlation between thin-section CT findings and pathologic subgroups in 55 patients Radiology 225 199 204 12355005 10.1148/radiol.2251011555
10. RK Hoyles RW Ellis J Wellsbury B Lees P Newlands NS Goh C Roberts S Desai AL Herrick NJ McHugh NM Foley SB Pearson P Emery DJ Veale CP Denton AU Wells CM Black RM du Bois 2006 A multicenter, prospective, randomized, double-blind, placebo-controlled trial of treatment with corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis Rheum 54 3962 3970 17133610 10.1002/art.22204 1:CAS:528:DC%2BD2sXktlalug%3D%3D (Pubitemid 44955900)
11. DP Tashkin R Elashoff PJ Clements J Goldin MD Roth DE Furst E Arriola R Silver C Strange M Bolster JR Seibold DJ Riley VM Hsu J Varga DE Schraufnagel A Theodore R Simms R Wise F Wigley B White V Steen C Read M Mayes E Parsley K Mubarak MK Connolly J Golden M Olman B Fessler N Rothfield M Metersky Scleroderma Lung Study Research Group 2006 Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655 2666 16790698 10.1056/NEJMoa055120 1:CAS:528:DC%2BD28XmtFSgtLs%3D
12. J Goldin R Elashoff HJ Kim X Yan D Lynch D Strollo MD Roth P Clements DE Furst D Khanna S Vasunilashorn G Li DP Tashkin 2009 Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study Chest 136 1333 1340 19892673 10.1378/chest.09-0108 1:CAS:528:DC%2BD1MXhsFChtLfK
13. FJ Martinez WJ McCune 2006 Cyclophosphamide for scleroderma lung disease N Engl J Med 354 2707 2709 16790705 10.1056/NEJMe068095 1:CAS:528: DC%2BD28XmtFSgsb0%3D
14. AS Morgenthau ML Padilla 2009 Spectrum of fibrosing diffuse parenchymal lung disease Mt Sinai J Med 76 2 23 19170214 10.1002/msj.20087
15. HJ Kim G Li D Gjertson R Elashoff SK Shah R Ochs F Vasunilashorn F Abtin MS Brown JG Goldin 2008 Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study Acad Radiol 15 1004 1016 18620121 10.1016/j.acra.2008.03.011 (Pubitemid 351938744)
16. HJ Kim DP Tashkin PJ Clements G Li MS Brown R Elashoff DW Gjertson F Abtin DA Lynch DC Strollo JG Goldin 2010 A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients Clin Exp Rheumatol 5 S26 S35
17. CD Collins AU Wells DM Hansell RA Morgan JE MacSweeney RM du Bois MB Rubens 1994 Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography and chest radiography Clin Radiol 49 236 240 8162678 10.1016/S0009-9260(05)81847-1 1:STN:280:DyaK2c3hsFaruw%3D%3D (Pubitemid 24107999)
18. G Camiciottoli I Orlandi M Bartolucci E Meoni F Nacci S Diciotti C Barcaroli ML Conforti M Pistolesi M Matucci-Cerinic M Mascalchi 2007 Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life Chest 131 672 681 17356079 10.1378/chest.06-1401 (Pubitemid 46446856)
19. DA Lynch 2007 Quantitative CT of fibrotic interstitial lung disease Chest 131 643 644 17356073 10.1378/chest.06-2955 (Pubitemid 46446850)
20. H Sumikawa T Johkoh S Yamamoto M Yanagawa A Inoue O Honda S Yoshida N Tomiyama H Nakamura 2009 Computed tomography values calculation and volume histogram analysis for various computed tomographic patterns of diffuse lung diseases J Comput Assist Tomogr 33 731 738 19820502 10.1097/RCT.0b013e31818da65c
21. R Uppaluri EA Hoffman M Sonka PG Hartley GW Hunninghake G McLennan 1999 Computer recognition of regional lung disease patterns Am J Respir Crit Care Med 160 648 654 10430742 1:STN:280:DyaK1MzlvFOisw%3D%3D (Pubitemid 29380686)
22. F Chabat GZ Yang DM Hansell 2003 Obstructive lung diseases: texture classification for differentiation at CT Radiology 228 871 877 12869685 10.1148/radiol.2283020505 (Pubitemid 37025501)
23. HF Boehm C Fink U Attenberger C Becker J Behr M Reiser 2008 Automated classification of normal and pathologic pulmonary tissue by topological texture features extracted from multi-detector CT in 3D Eur Radiol 18 2745 2755 18618121 10.1007/s00330-008-1082-y 1:STN:280:DC%2BD1cjivVyrtA%3D%3D
24. A Depeursinge J Iavindrasana A Hidki G Cohen A Geissbuhler A Platon PA Poletti H Muller 2010 Comparative performance analysis of state-of-the-art classification algorithms applied to lung tissue categorization Digit Imaging 23 18 30 10.1007/s10278-008-9158-4
25. VA Zavaletta BJ Bartholmai RA Robb 2007 High resolution multidetector CT-aided tissue analysis and quantification of lung fibrosis Acad Radiol 14 772 787 17574128 10.1016/j.acra.2007.03.009 (Pubitemid 46898849)
26. T Iwasawa A Asakura F Sakai T Kanauchi T Gotoh T Ogura T Yazawa J Nishimura T Inoue 2009 Assessment of prognosis of patients with idiopathic pulmonary fibrosis by computer-aided analysis of CT images J Thorac Imaging 24 216 222 19704326 10.1097/RTI.0b013e3181a6527d
27. Y Arzhaeva M Prokop K Murphy EM van Rikxoort PA de Jong HA Gietema MA Viergever B van Ginneken 2010 Automated estimation of progression of interstitial lung disease in CT images Med Phys 37 63 73 20175467 10.1118/1.3264662
28. AC Best J Meng AM Lynch CM Bozic D Miller GK Grunwald DA Lynch 2008 Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality Radiology 246 935 940 18235106 10.1148/radiol.2463062200
29. DA Mahler DH Weinberg CK Wells AR Feinstein 1984 The measurement of dyspnea: contents, interobserver agreement and physiologic correlates of two new clinical indexes Chest 85 751 758 6723384 10.1378/chest.85.6.751 1:STN:280:DyaL2c3gs12rsA%3D%3D (Pubitemid 14121920)
30. JG Goldin DA Lynch DC Strollo RD Suh DE Schraufnagel PJ Clements RM Elashoff DE Furst S Vasunilashorn MF McNitt-Gray MS Brown MD Roth DP Tashkin Scleroderma Lung Study Research Group 2008 High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease Chest 134 358 367 18641099 10.1378/chest.07-2444
31. JM Bland DG Altman 1986 Statistical methods for assessing agreement between two methods of clinical measurement Lancet 1 307 310 2868172 10.1016/S0140-6736(86)90837-8 1:STN:280:DyaL287hslWqsQ%3D%3D (Pubitemid 16134762)
32. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ, Scleroderma Lung Study Group (2007) Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 56(5):1676-1684 (Pubitemid 46764099)
33. AU Wells J Behr R Silver 2008 Outcome measures in the lung Rheumatology 47 Suppl 5 v48 v50 18784144 10.1093/rheumatology/ken311
34. RL Prentice 1989 Surrogate endpoints in clinical trials: definitions and operational criteria Stat Med 8 431 440 2727467 10.1002/sim.4780080407 1:STN:280:DyaL1M3ms1aktg%3D%3D (Pubitemid 19105891)
35. M Buyse G Molenberghs T Burzykowski D Renard H Geys 2000 The validation of surrogate endpoints in meta-analyses of randomized experiments Biostatistics 1 49 67 12933525 10.1093/biostatistics/1.1.49 (Pubitemid 33213521)
36. CA Altar D Amakye D Bounos J Bloom G Clack R Dean V Devanarayan D Fu S Furlong L Hinman C Girman C Lathia L Lesko S Madani J Mayne J Meyer D Raunig P Sager SA Williams P Wong K Zerba 2008 A Prototypical process for creating evidentiary standards for biomarkers and Diagnostics Clin Pharmacol Ther 83 368 371 18091762 10.1038/sj.clpt.6100451 1:STN:280:DC%2BD1c%2FkvValsA%3D%3D